Denosumab Biosimilars: Accelerating Drug Development for RANKL Inhibitors

Denosumab represents one of the leading biologics applied today in various diseases of bones: treatment and prevention of osteoporosis, bone metastases, and other skeletal disorders. Its success in improving patient health has made it one of the most impactful therapies in its field. With the growth of the biosimilar market in recent years and (...)

Read more

By |2025-01-27T10:00:27+01:00January 23rd, 2025|Bioanalysis, Service|Comments Off on Denosumab Biosimilars: Accelerating Drug Development for RANKL Inhibitors

Liraglutide & Semaglutide: Exploring Biosimilar Studies for GLP-1 receptor agonists

Liraglutide and Semaglutide have become key players in the pharmaceutical and healthcare industry as they are both being used and have been approved not only as an anti-diabetic medication but also as an obesity and weight loss treatment. In combination with the huge growth of the biosimilar market in recent years and their patent expiry (...)

Read more

By |2024-08-14T10:52:27+02:00February 20th, 2024|Bioanalysis, CMC, Service|Comments Off on Liraglutide & Semaglutide: Exploring Biosimilar Studies for GLP-1 receptor agonists